Fig 1: Mrp8/14-induced BV2 microglia activation was alleviated by a TLR4 inhibitor (TAK-242). Cells were administrated with TAK-242 for 30 min before treatment of Mrp8/14 heterodimer. a The iNOS protein level was reduced in Mrp8/14 + TAK-242 group compared with Mrp8/14 group (n = 4 per group). b The iNOS mRNA level was reduced in Mrp8/14 + TAK-242 group compared with Mrp8/14 group (n = 3–4 per group). c The production of nitric oxide (NO) induced by Mrp8/14 was decreased when pretreatment of TAK-242 (n = 3–4 per group). d The representative photos exhibited that the production of reactive oxygen species (ROS) induced by Mrp8/14 was reduced when pretreatment of TAK-242. *p < 0.05, **p < 0.01, ***p < 0.001 between two indicated groups
Fig 2: iNOS and PKG-1 expression in rat lungs. (a and b) iNOS and PKG-1 expression were measured by immunohistochemical analysis in three groups; there was a marked upregulation of iNOS (arrow in i-MCT) (a) and downregulation of PKG-1 (arrow in P-MCT) (b) in the lungs from MCT treated rats, downregulation iNOS and upregulation PKG-1after TMP treatment (arrow in i-MCT + TMP, P-MCT + TMP). (c) Western blot analysis demonstrated the iNOS and PKG-1 expression in rat lung homogenates. The bar graph showed iNOS and PKG-1 levels obtained from quantitative densitometry analysis. N = 12 per group. Data were mean ± SD, ##P < 0.01 vs. control group. **P < 0.01 vs. MCT group.
Supplier Page from Abcam for Anti-iNOS antibody [EPR16630]